Loading...
Loading...
AGLE| Name | Value |
|---|---|
| Revenues | 0.2M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.2M |
| Operating Expense | 18.9M |
| Operating I/L | -18.8M |
| Other Income/Expense | 0.3M |
| Interest Income | 0.3M |
| Pretax | -18.4M |
| Income Tax Expense | -0.2M |
| Net Income/Loss | -18.2M |
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of human enzyme therapeutics for rare metabolic diseases. The company's lead product candidate, pegzilarginase, is undergoing Phase III PEACE trial for the treatment of Arginase 1 deficiency. Additionally, it is developing AGLE-177, a polyethylene glycol modified, in Phase I/II clinical trial for homocystinuria treatment. Aeglea's preclinical pipeline includes AGLE-325 for cystinuria treatment and other research programs.
